Investments, Funding & Disinvestment

Through this agreement, Sanofi will gain full ownership of Heplisav-B, a two-dose hepatitis B vaccine that received US approval in 2017 and European authorization in 2021.

Through this acquisition, J&J gains access to HLD-0915, a clinical-stage, once-daily oral therapy intended for the treatment of prostate cancer.

This deal gives Samsung Biologics its first manufacturing site in the US and reinforces its long-term commitment to serving the North American biopharmaceutical market.

The project will generate between 500 and 700 direct jobs and feature advanced digital infrastructure to ensure operational efficiency, traceability, and robust quality control.

The newly constructed, purpose-built facility is designed to handle high potency drugs, including oncology and hormone products.

The biotechnology market was valued at USD 1.6 trillion in 2020 and is expected to grow at a compound annual growth rate of 14.2%, reaching USD 4.05 trillion by 2035.

Everest Medicines plans to deliver predictable near-term value through commercializing existing assets, forming business development partnerships, and achieving in-house research and development milestones.

Through this acquisition, Philips aims to enhance the precision and efficiency of coronary interventions, ultimately benefiting both healthcare professionals and patients.

These investments will focus primarily on companies developing breakthrough technologies in gastrointestinal (GI), urology, and respiratory care.

The Alabama site is part of Lilly’s USD 27 billion U.S. onshoring initiative, aimed at reinforcing domestic pharmaceutical manufacturing.